Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses the treatment trends in 2017 for estrogen receptor positive breast cancer, which include the use of CDK46 inhibitors. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.
Treatment Trends for Estrogen Receptor Positive Breast Cancer for 2017
